Suppliers and packagers for generic pharmaceutical drug: PLECANATIDE

PLECANATIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-01	1 BOTTLE in 1 CARTON (65649-003-01) / 1 TABLET in 1 BOTTLE	2017-02-21
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-03	1 BOTTLE in 1 CARTON (65649-003-03) / 3 TABLET in 1 BOTTLE	2017-02-21
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-07	1 BOTTLE in 1 CARTON (65649-003-07) / 7 TABLET in 1 BOTTLE	2017-02-21
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-30	30 TABLET in 1 BOTTLE (65649-003-30)	2017-02-21

Plecanatide Suppliers: Manufacturing Landscape Analysis

Last updated: February 19, 2026

This report details the current landscape of manufacturing suppliers for plecanatide, a guanylate cyclase-C agonist used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. The analysis focuses on key suppliers, their capabilities, and their role in the plecanatide supply chain.

Who Are the Primary Manufacturers of Plecanatide?

The manufacturing of plecanatide is primarily handled by specialized contract development and manufacturing organizations (CDMOs) with expertise in peptide synthesis and complex drug manufacturing. While the originator of plecanatide is Ironwood Pharmaceuticals (acquired by AbbVie), the production of the active pharmaceutical ingredient (API) and the finished drug product often involves third-party manufacturers.

Key entities involved in the plecanatide manufacturing ecosystem include:

• Contract Development and Manufacturing Organizations (CDMOs): These companies are contracted to produce the API and/or the finished dosage form. They possess the necessary infrastructure, regulatory compliance, and specialized expertise for peptide synthesis.
• Originator/Marketing Authorization Holder: Ironwood Pharmaceuticals (now part of AbbVie) holds the marketing authorization and oversees the overall supply chain, including the selection and management of CDMO partners.
• Analytical Testing Laboratories: Independent laboratories may be engaged for quality control, stability testing, and release testing of both the API and finished product.

Specific CDMOs identified in public disclosures or patent literature as being involved in the plecanatide supply chain include those with strong capabilities in:

• Peptide Synthesis: Plecanatide is a synthetic peptide, requiring specialized equipment and processes for its assembly.
• High-Potency API Handling: While not typically classified as highly potent, peptide APIs require careful handling to ensure purity and prevent degradation.
• cGMP Manufacturing: All manufacturing must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies like the FDA and EMA.

Identifying the exact current list of contracted manufacturers can be challenging due to confidentiality agreements common in the pharmaceutical industry. However, patent filings and regulatory submissions often provide clues regarding manufacturing sites. For example, patents related to plecanatide manufacturing processes or polymorphs may name specific companies or research institutions involved in process development.

What Are the Key Manufacturing Challenges for Plecanatide?

The manufacturing of peptide-based drugs like plecanatide presents distinct challenges compared to small molecule pharmaceuticals. These challenges impact yield, purity, scalability, and cost.

Key manufacturing challenges include:

• Peptide Synthesis Complexity:
  • Solid-Phase Peptide Synthesis (SPPS) or Liquid-Phase Peptide Synthesis (LPPS): Both methods require precise control over coupling reactions, deprotection steps, and purification. Amino acid coupling efficiency directly impacts overall yield and impurity profiles.
  • Chiral Purity: Maintaining the stereochemical integrity of each amino acid residue is critical for biological activity. Side reactions can lead to epimerization.
  • Side Chain Modifications: Plecanatide contains a disulfide bond, which requires controlled oxidation steps to form correctly. Incorrect disulfide bond formation can lead to inactive isomers.
  • Aggregation and Solubility: Peptides can be prone to aggregation during synthesis and purification, complicating downstream processing and affecting solubility in formulation buffers.
• Scale-Up:
  • Transitioning from laboratory-scale synthesis to commercial-scale production (kilograms to metric tons) requires significant process optimization.
  • Maintaining reaction consistency and impurity profiles across different scales is a major hurdle. Reactor size, mixing efficiency, and heat transfer dynamics change with scale.
• Purification:
  • Chromatography: High-performance liquid chromatography (HPLC), particularly reverse-phase HPLC (RP-HPLC), is the standard for purifying peptides. Achieving high purity (>98%) often requires multiple chromatographic steps.
  • Cost of Purification: Large-scale chromatographic purification is expensive, consuming significant amounts of solvents and stationary phases.
  • Yield Loss: Each purification step inevitably results in some loss of product, impacting overall process yield and cost.
• Stability and Storage:
  • Peptides can be susceptible to enzymatic degradation, oxidation, hydrolysis, and aggregation.
  • Lyophilization (freeze-drying) is often used for the API to enhance long-term stability, requiring specialized equipment and controlled environmental conditions.
• Regulatory Compliance:
  • Strict adherence to cGMP is mandatory throughout the manufacturing process, from raw material sourcing to final product release.
  • Process validation, analytical method validation, and robust quality control systems are essential for regulatory approval.
  • Controlling impurities, including process-related impurities, degradants, and residual solvents, is critical. Specific impurity thresholds are set by regulatory agencies.
• Cost of Goods (COGS):
  • The cost of highly purified amino acids, coupling reagents, solvents, and specialized equipment contributes to the high COGS for peptide drugs.
  • Low overall yields due to synthesis and purification inefficiencies further increase costs.

What Are the Regulatory Considerations for Plecanatide Suppliers?

Suppliers of plecanatide, whether for the API or the finished drug product, must meet rigorous regulatory standards set by global health authorities. These regulations ensure product quality, safety, and efficacy.

Key regulatory considerations include:

• cGMP Compliance:
  • All manufacturing facilities must be inspected and approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.
  • Adherence to the principles of cGMP, as outlined in ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and relevant regional guidelines, is fundamental. This includes strict controls over:
    • Facility design and maintenance
    • Equipment calibration and qualification
    • Raw material sourcing and testing
    • Process validation
    • Quality control and assurance systems
    • Documentation and record-keeping
    • Personnel training and hygiene
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):
  • API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, quality controls, and stability of the API.
  • The marketing authorization holder (e.g., AbbVie) references these DMFs in their drug product applications.
• Impurity Control:
  • Regulatory agencies set strict limits on various types of impurities:
    • Process-Related Impurities: Byproducts of the synthesis process, unreacted starting materials, reagents.
    • Degradation Products: Compounds formed during storage or handling.
    • Residual Solvents: Solvents used in manufacturing must be controlled to acceptable levels as per ICH Q3C guidelines.
    • Genotoxic Impurities: Particular scrutiny is applied to impurities with potential genotoxic activity.
  • Analytical methods must be validated to accurately detect and quantify these impurities.
• Stability Testing:
  • Extensive stability studies are required to determine the shelf-life of both the API and the finished drug product under various storage conditions (e.g., ICH Q1A(R2) guidelines).
  • This includes testing for physical, chemical, and microbiological stability.
• Change Control:
  • Any significant changes to the manufacturing process, suppliers, equipment, or analytical methods must be evaluated for their impact on product quality and may require regulatory notification or approval.
• Supply Chain Security:
  • Ensuring the integrity of the supply chain from raw materials to finished product is critical to prevent counterfeiting and contamination.
  • Traceability of materials is essential.
• Environmental, Health, and Safety (EHS) Regulations:
  • Manufacturers must comply with local and international EHS regulations, particularly concerning the handling of chemicals, waste disposal, and emissions.

What Are the Key Components of the Plecanatide Supply Chain?

The plecanatide supply chain is a multi-stage process involving various entities from raw material sourcing to the distribution of the finished drug product to patients. The complexity of peptide manufacturing necessitates a robust and well-managed chain.

The key components include:

• Raw Material Sourcing:
  • Protected Amino Acids: High-purity, protected amino acids are the fundamental building blocks. Suppliers must meet stringent quality specifications and have robust quality control systems.
  • Reagents and Solvents: Coupling reagents (e.g., HBTU, HATU), activating agents, deprotection reagents (e.g., TFA), and high-purity solvents (e.g., acetonitrile, DMF, water) are critical. Their quality directly influences synthesis outcomes.
  • Chromatographic Media: Specialized resins for RP-HPLC are essential for purification.
• Active Pharmaceutical Ingredient (API) Manufacturing:
  • This stage involves the synthesis and purification of plecanatide itself. It is typically performed by specialized CDMOs with expertise in peptide chemistry.
  • Process: Solid-phase or liquid-phase peptide synthesis, followed by cleavage, deprotection, and disulfide bond formation.
  • Purification: Multiple RP-HPLC steps are common to achieve the required purity.
  • Lyophilization: The purified API is often lyophilized for enhanced stability.
  • Quality Control: Rigorous testing of the API for identity, purity, assay, related substances, residual solvents, and microbial limits.
• Drug Product Formulation:
  • The API is combined with excipients to create the finished dosage form. Plecanatide is administered orally as tablets.
  • Excipients: Include fillers (e.g., microcrystalline cellulose), binders (e.g., povidone), disintegrants (e.g., croscarmellose sodium), lubricants (e.g., magnesium stearate), and film-coating agents. These must be of pharmaceutical grade.
  • Formulation Development: Optimizing the formulation to ensure API stability, dissolution, and bioavailability.
• Finished Drug Product Manufacturing:
  • This involves the processes of blending, granulation (if applicable), tableting, and film coating.
  • Performed by CDMOs specializing in solid dosage forms or by the originator's manufacturing sites.
  • cGMP Adherence: Strict adherence to cGMP for all unit operations.
• Packaging and Labeling:
  • Primary packaging (e.g., blister packs, bottles) and secondary packaging.
  • Labeling must comply with regulatory requirements for the target markets.
  • Serialization and track-and-trace systems are increasingly important for supply chain security.
• Quality Control and Assurance:
  • Throughout the entire process, QC laboratories conduct in-process controls and final product testing.
  • QA oversees all aspects of the manufacturing and supply chain to ensure compliance and product quality.
• Warehousing and Distribution:
  • Storage of API and finished product under controlled conditions.
  • Logistics management for timely delivery to wholesalers, distributors, and pharmacies.
  • Cold chain management may be required depending on product stability requirements, though plecanatide API is typically lyophilized for ambient storage.

How Does Plecanatide's Manufacturing Differ from Other Constipation Treatments?

Plecanatide's manufacturing profile is distinct due to its nature as a synthetic peptide, differentiating it significantly from other classes of laxatives and constipation treatments that are typically small molecules or naturally derived.

Plecanatide (Synthetic Peptide):

• API Manufacturing: Complex, multi-step synthesis involving Solid-Phase Peptide Synthesis (SPPS) or Liquid-Phase Peptide Synthesis (LPPS). Requires specialized peptide synthesizers, automated coupling and deprotection steps, and extensive purification, often using preparative High-Performance Liquid Chromatography (HPLC).
• Raw Materials: High-purity protected amino acids, coupling reagents, and specialized solvents.
• Purification: Primarily chromatographic methods (RP-HPLC), which are resource-intensive and can lead to significant yield loss.
• Stability: Peptides can be prone to aggregation and degradation. Lyophilization is often employed to enhance API stability, increasing manufacturing complexity and cost.
• Cost of Goods: Generally higher due to the complex synthesis, expensive raw materials, and extensive purification required.
• Scalability: Challenges in scaling up peptide synthesis while maintaining purity and yield.
• Regulatory Scrutiny: Focus on peptide-specific impurities and the complexity of the manufacturing process.

Other Constipation Treatments and Their Manufacturing Differences:

• Bulk-Forming Laxatives (e.g., Psyllium, Methylcellulose):
  • API Manufacturing: Primarily involve harvesting, processing, and purification of plant-based fibers or synthetic polymers. Manufacturing is generally less complex than peptide synthesis.
  • Raw Materials: Natural sources or bulk polymer production.
  • Purification: Typically involves physical separation methods, milling, and sieving.
  • Stability: Generally stable under ambient conditions.
  • Cost of Goods: Significantly lower.
  • Scalability: Relatively straightforward.
• Osmotic Laxatives (e.g., Polyethylene Glycol, Magnesium Citrate, Lactulose):
  • API Manufacturing:
    • Polyethylene Glycol (PEG): Synthesized via polymerization of ethylene oxide. A well-established chemical process.
    • Magnesium Citrate: Typically produced by reacting magnesium oxide or hydroxide with citric acid. A relatively simple inorganic/organic salt formation.
    • Lactulose: Produced by isomerizing lactose under alkaline conditions. A chemical modification of a sugar.
  • Raw Materials: Petrochemicals (for PEG), inorganic salts and organic acids, sugars.
  • Purification: Standard chemical purification techniques, crystallization, filtration.
  • Stability: Generally stable.
  • Cost of Goods: Moderate to low.
  • Scalability: Generally straightforward.
• Stimulant Laxatives (e.g., Bisacodyl, Sennosides):
  • API Manufacturing:
    • Bisacodyl: A synthetic organic molecule, manufactured through multi-step organic synthesis.
    • Sennosides: Extracted from senna leaves, followed by purification.
  • Raw Materials: Organic chemicals for synthesis, plant material for extraction.
  • Purification: Chemical synthesis purification (crystallization, chromatography) for bisacodyl; extraction and purification for sennosides.
  • Stability: Generally stable.
  • Cost of Goods: Moderate.
  • Scalability: Achievable through established chemical engineering principles.
• Stool Softeners (e.g., Docusate Sodium):
  • API Manufacturing: Synthetic organic chemistry process involving esterification reactions.
  • Raw Materials: Organic acids, alcohols, and surfactants.
  • Purification: Standard chemical purification.
  • Stability: Generally stable.
  • Cost of Goods: Low to moderate.
  • Scalability: Straightforward.

In summary, plecanatide's peptide nature places its manufacturing squarely in the complex and high-cost category, demanding specialized CDMOs and rigorous process control, unlike the more conventional chemical synthesis or extraction/processing methods employed for other constipation treatments.

Key Takeaways

• Plecanatide API and finished product manufacturing is primarily handled by specialized Contract Development and Manufacturing Organizations (CDMOs) with expertise in peptide synthesis and cGMP compliance.
• The synthesis and purification of plecanatide present significant challenges, including complex peptide coupling, disulfide bond formation, extensive chromatographic purification, and potential for aggregation, all contributing to higher manufacturing costs and lower yields compared to small molecule drugs.
• Suppliers must adhere to stringent global regulatory standards, including cGMP, and manage impurity profiles, stability, and supply chain integrity. Drug Master Files (DMFs) are critical for API suppliers to interface with regulatory agencies.
• The plecanatide supply chain encompasses raw material sourcing, API synthesis and purification, drug product formulation and manufacturing, packaging, and distribution, each requiring specific quality controls and regulatory oversight.
• Plecanatide's manufacturing process is inherently more complex and costly than that of most other constipation treatments, which typically involve standard chemical synthesis, extraction, or physical processing of fibers.

FAQs

1. What is the typical lead time for securing plecanatide API from a CDMO? Lead times for plecanatide API can vary significantly, ranging from 12 to 24 months or more, depending on the CDMO's existing capacity, the scale of production required, and the complexity of process validation and regulatory documentation.

2. Are there specific excipients that are particularly challenging to source for plecanatide tablet formulations? While standard pharmaceutical excipients like microcrystalline cellulose, povidone, and magnesium stearate are generally widely available, ensuring a consistent supply of high-purity grades from qualified suppliers who meet cGMP requirements is crucial. For peptides, ensuring excipient compatibility and lack of reactivity that could degrade the API is paramount.

3. Does the manufacturing process for plecanatide generate significant waste products? Yes, peptide synthesis and purification, particularly through RP-HPLC, utilize large volumes of solvents (e.g., acetonitrile, water, trifluoroacetic acid). Proper waste management and solvent recovery systems are critical for environmental compliance and cost control.

4. How is the disulfide bond in plecanatide formed and controlled during manufacturing? The disulfide bond is typically formed through a controlled oxidation step after the linear peptide chain is synthesized. Common methods involve using oxidizing agents like atmospheric oxygen (sometimes with catalysts), potassium ferricyanide, or iodine, under carefully controlled pH and concentration conditions to favor intra-molecular disulfide bond formation and minimize inter-molecular cross-linking.

5. What are the primary analytical techniques used to ensure the purity and identity of plecanatide API? Primary analytical techniques include High-Performance Liquid Chromatography (HPLC) for purity and impurity profiling, Mass Spectrometry (MS) for identity confirmation and molecular weight verification, Amino Acid Analysis (AAA) to confirm the amino acid composition and stoichiometry, and potentially techniques like Nuclear Magnetic Resonance (NMR) for structural elucidation and peptide sequencing.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. U.S. Department of Health and Human Services. [2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry ICH Q3C Impurities: Guidelines for Residual Solvents. U.S. Department of Health and Human Services. [3] U.S. Food and Drug Administration. (n.d.). Guidance for Industry ICH Q1A(R2) Stability Testing of New Drug Substances and Products. U.S. Department of Health and Human Services. [4] Ironwood Pharmaceuticals. (2017). LINZESS® (linaclotide) Prescribing Information. Retrieved from [Relevant official prescribing information source, if available publicly] [5] AbbVie Inc. (2023). AbbVie Completes Acquisition of Allergan plc. [Press Release]. Retrieved from [Official AbbVie Investor Relations News Release Archive]